What is RoBaCO?
The Efficacy and Safety of Rosuvastatin for Modifying Bone Mass and Cardiometabolic Disease Outcomes (RoBaCO Trial) is a collaborative, multi-center clinical trial conducted between Toronto Rehabilitation Institute Lyndhurst Centre and the University of Miami Miller School of Medicine.
Clinical trials explore which treatments works best for certain illnesses or groups of people.
What is the purpose of the study?
Long-term spinal cord injury (SCI) can lead to decreased bone strength and cardiometabolic health. As a result, SCI can increase the risk of fracture and cardiometabolic disease (i.e. diabetes, dyslipidemia, and coronary artery disease).
Although there are medications to treat bone and cardiometabolic health, there is currently no known treatment that addresses both of these concerns. However, recent research suggests that statins may be an exception to this statement.
Statins are a type of medication normally used to treat high cholesterol, but studies have shown statins may also have the ability to improve bone health. The primary focus of our study is to determine if statins (Rosuvastatin) can safely and effectively improve bone and cardiometabolic health in adults with SCI.
We hope that our research can help enable individuals with SCI to live full and productive lives as active participants in their communities.
How can you get involved?
If you would like to volunteer as a RoBaCO research participant, please contact us at
Please note that the security of e-mail messages is not guaranteed. Messages may be forged, forwarded, kept indefinitely, or seen by others using the internet. Do not use e-mail to discuss information you think is sensitive. Do not use e-mail in an emergency since e-mail may be delayed.
If you decide to participate in the study, all information you provide will be confidential. Your name will not appear on any forms. You can stop participating at any time without having to give a reason.
Check out the following links for more information on RoBaCO, Spinal Cord Injury, or contact us: